EV Battery Integration Explained | IBIS Technology
Stellantis has unveiled its revolutionary IBIS battery, which integrates the charger and inverter to create a lighter, more efficient, and cost-effective EV powertrain. This innovation could accelerate the adoption of electric vehicles and create growth opportunities for companies supplying advanced components and materials to the battery and energy storage industries.
Your Basket's Financial Footprint
Basket market capitalisation details and investor takeaways.
- Large-cap dominance generally implies lower volatility, more stable returns and closer tracking of broad market movements.
- Use this basket as a core holding for diversified exposure, not as a speculative short-term trade.
- Expect steady, long-term value rather than explosive short-term gains; growth tends to be gradual and uncertain.
QS: $8.78B
AMPX: $1.53B
MVST: $1.86B
- Other
About This Group of Stocks
Our Expert Thinking
Stellantis's breakthrough IBIS battery technology represents a fundamental shift in EV design, integrating chargers and inverters directly into battery packs. This innovation could dramatically reduce manufacturing costs and accelerate mass-market EV adoption, creating significant opportunities for companies across the entire supply chain from advanced materials to power electronics.
What You Need to Know
This group focuses on companies positioned to benefit from the integrated battery revolution, spanning battery materials, thermal management systems, and energy storage solutions. These stocks represent tactical exposure to a key innovation cycle that could reshape not just automotive but also rail, aerospace, and data centre applications.
Why These Stocks
Each company in this selection was handpicked by professional analysts for their strategic positioning within the integrated EV battery ecosystem. They represent suppliers of critical components, advanced materials, and technologies essential for next-generation battery systems that could define the future of electric mobility.
Why You'll Want to Watch These Stocks
Revolutionary Technology Breakthrough
Stellantis's IBIS system could fundamentally change how EVs are built, making them lighter, cheaper, and faster to charge. This breakthrough could trigger a wave of innovation across the entire industry.
Mass Market Acceleration
Lower manufacturing costs from integrated battery systems could finally make EVs affordable for mainstream consumers. Companies in this space are positioned to benefit from this potential surge in demand.
Beyond Automotive Applications
This integrated battery technology isn't just for cars - it could transform rail, aerospace, and data centre energy storage. These companies are at the forefront of multiple growth markets.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Railroad Investment: Beyond the $85 Billion Merger
Union Pacific and Norfolk Southern are seeking to merge, creating America's first transcontinental railroad. This landmark consolidation could drive significant investment into rail infrastructure and technology, creating opportunities for companies that support and equip the freight rail industry.
Oracle TikTok Deal May Boost Stocks in 2025
TikTok has finalized the sale of its U.S. operations to an investor group including Oracle, resolving national security concerns and securing its future in the American market. This development creates opportunities for companies in the digital advertising, social commerce, and creator economy sectors that can now capitalize on the platform's stabilized presence and massive user base.
Pharma Reshoring Explained | Manufacturing Investment
Major pharmaceutical firms have signed agreements with the U.S. government to lower drug prices in exchange for tariff exemptions and other concessions. This move is expected to drive over $150 billion in new domestic R&D and manufacturing investments, creating opportunities for U.S.-based life sciences and industrial supply chain companies.